NCT00186823View on ClinicalTrials.gov

Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

September 30, 2005

Study Completion Date

January 31, 2009

Conditions
Leukemia, Acute Lymphocytic (ALL)Leukemia, Myeloid, Acute(AML)Leukemia, Myeloid, Chronic(CML)Juvenile Myelomonocytic Leukemia(JMML)Hemoglobinuria, Paroxysmal Nocturnal (PNH)Lymphoma, Non-Hodgkin (NHL)Myelodysplastic Syndrome (MDS)
Interventions
DEVICE

Miltenyi Biotec CliniMACS

A stem cell selection device.

PROCEDURE

Stem Cell Transplantation

An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

DRUG

TBI, systemic chemotherapy and antibodies as follows:

Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00186823 - Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter